drug_type
RELEVANT_DRUG
intervention_type
Cytotoxic small-molecule (microtubule inhibitor)
drug_description
Potent microtubule inhibitor (auristatin class) serving as the cytotoxic payload in the RC48-ADC; disrupts tubulin polymerization leading to mitotic arrest and apoptosis. In this trial it is delivered only via the disitamab vedotin conjugate, not as free drug.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Monomethyl Auristatin E
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Monomethyl auristatin E (MMAE) is an auristatin microtubule inhibitor that binds tubulin and blocks polymerization, inducing G2/M mitotic arrest and apoptosis. In this trial it is released intracellularly as the cytotoxic payload of the HER2-targeted ADC disitamab vedotin (RC48), enabling targeted killing of HER2-expressing tumor cells with potential bystander effect.
drug_name
Monomethyl auristatin E (MMAE)
nct_id_drug_ref
NCT05996952